Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

October 22, 2023

Must read

Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

Source link

Goldman Sachs Backs Amazon Stock Despite Investor Concerns

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

Must read

Alaska Energy Metals Announces Flow-Through Financing; Acquisition Update and IR Developments

Pound Dollar Prediction: Navigating the Currency Market

Bluebird Bio’s Hold Rating Maintained Amid Launch Challenges and Market Competition

Death Put: Definition and Real-world Examples Revealed

More articles

Latest article

Alaska Energy Metals Announces Flow-Through Financing; Acquisition Update and IR Developments

Pound Dollar Prediction: Navigating the Currency Market

Bluebird Bio’s Hold Rating Maintained Amid Launch Challenges and Market Competition

Death Put: Definition and Real-world Examples Revealed

Raymond James says Sunnova Energy selloff an ‘overreaction’

Popular Category

Market News

Korn Ferry (NYSE:KFY) Follows Up Q2 Beat with 83% Dividend Boost

Sale of Student Loan Business Rockets Discover Financial Services (NYSE:DFS) Upward

Editor Picks

Alaska Energy Metals Announces Flow-Through Financing; Acquisition Update and IR Developments

Pound Dollar Prediction: Navigating the Currency Market

Interesting Stuff

Alaska Airlines and Hawaiian Airlines to Combine, Expanding Benefits and Choice for Travelers Throughout Hawai’i and the West Coast

How Bank of China Exchange Rate Battles Amid Moody’s Cuts